Biomarin Pharmaceutical Inc. (BMRN)

BMRN (NASDAQ:Drugs)
$58.31
pos +0.14
+0.24%
Today's Range: 57.21 - 58.78 | BMRN Avg Daily Volume: 1,450,600
Last Update: 06/18/13 - 4:00 PM EDT
Volume: 835,824
YTD Performance: 18.17%
Open: $58.05
Previous Close: $58.17
52 Week Range: $35.99 - $71.56
Oustanding Shares: 139,010,175
Market Cap: 8,082,051,575
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 12 12 13
Moderate Buy 1 1 1 1
Hold 3 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.39 1.53 1.53 1.50
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -55.37
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-55.37 0.00 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.81% 58.20% 192.31%
GROWTH 12 Mo 3 Yr CAGR
Revenue 13.50 0.54 0.15
Net Income 0.00 233.32 0.00
EPS 0.00 0.00 0.00
Earnings for BMRN:
EBITDA -0.06B
Revenue 0.50B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $-0.28 $-0.32 $-1.28 $-0.75
Number of Analysts 11 11 15 13
High Estimate $-0.23 $-0.24 $-1.00 $-0.20
Low Estimate $-0.33 $-0.37 $-1.43 $-1.47
Prior Year $-0.27 $-0.04 $-0.95 $-1.28
Growth Rate (Year over Year) -3.70% -690.91% -34.46% 41.34%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Mad Money Uncovered: ASCO

By

Jim Cramer

 | Jun 3, 2013 | 11:25 AM EDT

Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken

bullishBioMarin Pharmaceutical price target raised at Citi

May 31, 2013 | 7:59 AM EDT

BMRN price target was raised to $79 as anti-cancer drug BMN-673 was included in the model, said Citigroup.

updateBiomarin rated new Neutral at Credit Suisse

May 31, 2013 | 7:22 AM EDT

BMRN was initiated with a Neutral rating, Credit Suisse said. Valuation call, based on a $68 price target. 

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

By

Jim Cramer

 | Apr 2, 2013 | 11:58 AM EDT

Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken

A Deep Post-Decline Analysis Part 2

By

Jim Cramer

 | Feb 25, 2013 | 8:30 AM EST

Stocks that defy correction and those ripe for correction.

The Beat Goes On

By

James "Rev Shark" DePorre

 | Feb 19, 2013 | 10:18 AM EST

The slow, steady push higher continues.

The Next Big Thing In Biotech: BIO CEO Conference

By

Adam Feuerstein

 | Feb 7, 2013 | 11:38 AM EST

Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.

Trick of the Trading

By

James "Rev Shark" DePorre

 | Feb 5, 2013 | 10:53 AM EST

It's the bulls' turn to shine.

bullishBiomarin upgraded at Stifel

Jan 22, 2013 | 8:28 AM EST

BMRN was upgraded from Hold to Buy, Stifel Nicolaus said. $67 price target. New products should drive growth and the company is a potential acquisition target. 

The Next Big Thing In Biotech: JP Morgan Conference

By

Adam Feuerstein and Gregg Greenberg

 | Jan 4, 2013 | 5:00 AM EST

Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.

Columnist Conversation / Market Updates

Pool Corp (POOL): Under Water
By

Chris Laudani

 | Jun 18, 2013 | 4:41 PM EDT
Pool builder is getting pulled under by a strong rip tide after hours. Co lowers FY 13 guidance to $2.03 to $2.13 from ...

Little Interest in CAT
By

Gary Morrow

 | Jun 18, 2013 | 3:53 PM EDT
CAT is on pace to put in its lightest positive volume day of the year. The stock is up just shy of 1% but remains...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.